Latest News

Sign up to receive our news releases

More SomaLogic News

SomaLogic signs collaborative agreement with Novo Nordisk to support drug development efforts

SomaLogic, Inc., a global leader in proteomics technology, announced today that it is adding to its list of collaborative agreements with global healthcare innovator, Novo Nordisk. As part of the agreement, Novo Nordisk will expand the use of the SomaScan® technology platform for their drug development research in non-alcoholic steatohepatitis (NASH), cardiovascular disease and diabetes.

read more

Events Archive

Global NASH Congress | Webinar

Our presentation at the virtual 2021 Global Nash Congress features Dr. Stephen Williams , who discusses SomaLogics development of serum proteomic tests for liver biopsy components and diagnosis of at-risk NASH. Watch now to learn how these tests can help streamline clinical trials.

watch here

The Somascan® Assay: Biomarker Discovery to Delivery | Virtual Event

As part of the Molecular Medicine Tri-Con virtual conference on February 16, 2021, Dr. Sheri Wilcox of SomaLogic described how the SomaScan Assay has been used to identify protein patterns as surrogates for clinical outcomes, discover proteins associated with disease states, and correlate protein measurements with genetic variants.

watch here

New study shows consistency in proteogenomic signals between proteomic measurement platforms

Researchers at the University of Cambridge report the largest, systematic assessment of two different affinity-based proteomic platform technologies to date. By truncating the 5000-plex aptamer-based SomaScan® Assay results down to consider approximately 900 overlapping targets on a polyclonal antibody-based assay and running both assays on the same 485 genotyped samples, the researchers successfully replicated most proteogenomic signals on both platforms.

read more

For older news and press releases, please visit our archive.